|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CRBN |
Gene summary for CRBN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CRBN | Gene ID | 51185 |
| Gene name | cereblon | |
| Gene Alias | MRT2 | |
| Cytomap | 3p26.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96SW2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51185 | CRBN | LZE4T | Human | Esophagus | ESCC | 8.87e-10 | 2.53e-01 | 0.0811 |
| 51185 | CRBN | LZE7T | Human | Esophagus | ESCC | 3.88e-04 | 2.34e-01 | 0.0667 |
| 51185 | CRBN | LZE24T | Human | Esophagus | ESCC | 2.43e-09 | 3.14e-01 | 0.0596 |
| 51185 | CRBN | LZE6T | Human | Esophagus | ESCC | 1.10e-02 | 1.81e-01 | 0.0845 |
| 51185 | CRBN | P1T-E | Human | Esophagus | ESCC | 9.84e-05 | 1.59e-01 | 0.0875 |
| 51185 | CRBN | P2T-E | Human | Esophagus | ESCC | 1.24e-19 | 2.01e-01 | 0.1177 |
| 51185 | CRBN | P4T-E | Human | Esophagus | ESCC | 3.20e-16 | 4.18e-01 | 0.1323 |
| 51185 | CRBN | P5T-E | Human | Esophagus | ESCC | 2.38e-15 | 3.32e-01 | 0.1327 |
| 51185 | CRBN | P8T-E | Human | Esophagus | ESCC | 2.36e-18 | 2.61e-01 | 0.0889 |
| 51185 | CRBN | P9T-E | Human | Esophagus | ESCC | 2.58e-11 | 1.96e-01 | 0.1131 |
| 51185 | CRBN | P10T-E | Human | Esophagus | ESCC | 5.38e-17 | 3.05e-01 | 0.116 |
| 51185 | CRBN | P11T-E | Human | Esophagus | ESCC | 1.63e-05 | 2.21e-01 | 0.1426 |
| 51185 | CRBN | P12T-E | Human | Esophagus | ESCC | 2.14e-29 | 4.86e-01 | 0.1122 |
| 51185 | CRBN | P15T-E | Human | Esophagus | ESCC | 1.35e-15 | 2.15e-01 | 0.1149 |
| 51185 | CRBN | P16T-E | Human | Esophagus | ESCC | 5.61e-21 | 3.64e-01 | 0.1153 |
| 51185 | CRBN | P17T-E | Human | Esophagus | ESCC | 7.92e-06 | 3.14e-01 | 0.1278 |
| 51185 | CRBN | P20T-E | Human | Esophagus | ESCC | 7.04e-20 | 4.37e-01 | 0.1124 |
| 51185 | CRBN | P21T-E | Human | Esophagus | ESCC | 3.63e-09 | 1.28e-01 | 0.1617 |
| 51185 | CRBN | P22T-E | Human | Esophagus | ESCC | 1.63e-18 | 2.60e-01 | 0.1236 |
| 51185 | CRBN | P23T-E | Human | Esophagus | ESCC | 7.92e-30 | 6.48e-01 | 0.108 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:0031333110 | Esophagus | ESCC | negative regulation of protein-containing complex assembly | 86/8552 | 141/18723 | 1.74e-04 | 1.14e-03 | 86 |
| GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
| GO:004316112 | Liver | Cirrhotic | proteasome-mediated ubiquitin-dependent protein catabolic process | 184/4634 | 412/18723 | 4.52e-19 | 8.85e-17 | 184 |
| GO:004325412 | Liver | Cirrhotic | regulation of protein-containing complex assembly | 169/4634 | 428/18723 | 7.40e-12 | 4.99e-10 | 169 |
| GO:00313337 | Liver | Cirrhotic | negative regulation of protein-containing complex assembly | 64/4634 | 141/18723 | 7.08e-08 | 2.14e-06 | 64 |
| GO:00313347 | Liver | Cirrhotic | positive regulation of protein-containing complex assembly | 95/4634 | 237/18723 | 1.21e-07 | 3.39e-06 | 95 |
| GO:00510514 | Liver | Cirrhotic | negative regulation of transport | 141/4634 | 470/18723 | 5.06e-03 | 2.62e-02 | 141 |
| GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
| GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
| GO:004325422 | Liver | HCC | regulation of protein-containing complex assembly | 264/7958 | 428/18723 | 5.47e-16 | 4.39e-14 | 264 |
| GO:003133412 | Liver | HCC | positive regulation of protein-containing complex assembly | 150/7958 | 237/18723 | 7.35e-11 | 2.63e-09 | 150 |
| GO:003133312 | Liver | HCC | negative regulation of protein-containing complex assembly | 91/7958 | 141/18723 | 1.01e-07 | 1.98e-06 | 91 |
| GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
| GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
| GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
| GO:003133420 | Oral cavity | OSCC | positive regulation of protein-containing complex assembly | 153/7305 | 237/18723 | 1.18e-15 | 8.33e-14 | 153 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CRBN | SNV | Missense_Mutation | novel | c.1240N>C | p.Phe414Leu | p.F414L | Q96SW2 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CRBN | insertion | Frame_Shift_Ins | novel | c.948_949insGGTCTTAGCA | p.Lys317GlyfsTer11 | p.K317Gfs*11 | Q96SW2 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CRBN | SNV | Missense_Mutation | novel | c.311C>A | p.Pro104His | p.P104H | Q96SW2 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CRBN | SNV | Missense_Mutation | rs758183266 | c.316N>A | p.Glu106Lys | p.E106K | Q96SW2 | protein_coding | tolerated(0.13) | probably_damaging(0.992) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CRBN | SNV | Missense_Mutation | c.193G>A | p.Glu65Lys | p.E65K | Q96SW2 | protein_coding | deleterious(0.01) | possibly_damaging(0.676) | TCGA-3L-AA1B-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CRBN | SNV | Missense_Mutation | rs151127854 | c.332G>A | p.Arg111Gln | p.R111Q | Q96SW2 | protein_coding | tolerated(0.18) | probably_damaging(0.992) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRBN | SNV | Missense_Mutation | rs566932471 | c.1274N>T | p.Thr425Met | p.T425M | Q96SW2 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CRBN | SNV | Missense_Mutation | novel | c.1153G>A | p.Ala385Thr | p.A385T | Q96SW2 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRBN | SNV | Missense_Mutation | c.707N>C | p.Asn236Thr | p.N236T | Q96SW2 | protein_coding | tolerated(0.28) | benign(0.042) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CRBN | SNV | Missense_Mutation | novel | c.431A>G | p.Tyr144Cys | p.Y144C | Q96SW2 | protein_coding | deleterious(0.01) | probably_damaging(0.947) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | inhibitor | CHEMBL43452 | POMALIDOMIDE | |
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | inhibitor | CHEMBL468 | THALIDOMIDE | |
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | 178103899 | THALIDOMIDE | ||
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | 178103903 | LENALIDOMIDE | ||
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | 178103920 | POMALIDOMIDE | ||
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | CC-122 | AVADOMIDE | ||
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | 387065615 | |||
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | 387065622 | |||
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | 340590248 | IBERDOMIDE | ||
| 51185 | CRBN | ENZYME, DRUG RESISTANCE | 387065604 | AVADOMIDE |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |